Grant title for the next 5 years: Abstract: The theme of this award since its incejatipn In 1997 hias been to ghderstand how phosphorylation regulatds Opioid receptor slgnialirig. Iri'prior cycles, we defined sites bf opioid reclieptor phdsphoryl^itlon medisijting homologous, G-proteih receptor kinase 7. p-arrestin- dependehtr^ce|>torc|e8ensiti2^ip^^ In this rnu,opioid receptor and,pi[3;p^ signaling) V that;|Mntrol|edv jof;opioid;-receptof .;sigiriallngi;The,ii^phy^jologieai significance bf^tHMestyrosii:^ ph^fjllb^^ was est^Ilshed lay derhonstrailrig 4h(&lr ^i^qlejh #glJlatibri%plpid jSigjialiri^ ? :we!;prbp?is6 to ruridi^rstifhd'^hic^ rdgtilat^i'bS;'Juri-^ klnase;phosiphpiylitlbn'e>^^ kapipi? ppibld'r^^^pris^fdrmv slgnalirtg^cdilfvplexes:/^;Wi/^^ this previously. undiscp.verBd medris .pf.xe!ceptpri^^||,u^^ the .prpposed.flims: we: wpujd i) Id^nt^ thenSp^lhislril Sl^l^^ OfJgri,Kinase in tranisifeqteiififeK cells ieadihg from,opioid^feceptbr'actiy^tton.: to 4un Kin|ise.ijhbsphprylatibii Will be defined. 2J'We propose that theiopjoid receptor sld0e mecromplecular structure containing a jHlK-sensitive. cqmppnent reiq&li^ed fiprr^efnGi^ tb. the .effector. We will affinity purify the signaling cOmp|exahd.;identi|/the e^^ analysiSv This willbe usedvto ideiritiiythe'VfJK^h^^^^^ siilistrate withip the opldid receptor compiex. 3) The roles of specific cendldates'iden^^^^ aim #2 will be 'yalidated by targeted deletloFi and in wYw reboHstitutlpn'i^xp^^^^ the resulting bipchemiciiija^^;p^ibl6glcal:;.descHptIpns pf the opioid receptor signaling contiplex-Wiliprpvldei deeper Linder^^^^ Specific.
Aim #1 Morphine activation of the triu opioid receptor and norBNI activation ofthe kappa opioid receptor both result In Jun N-temiinal Kinase (JNK) phosphorylation, which subsequently causes oplold-receptor Ihactlvation. For MOR, this takes the forni of acute analgesic tolerance to morphine and for KOR, thls'Fesults In long-lasting antagon|srh. FOiir different .Intemnediate kinases have been Implicated In JNK'activatioii: ASKI, TAK1. MLK.- and. M6KK1. Using MOR-QFP and KOR-GFP expressing HEK293 celjs, we will use-dominant negative forms pf these potential mediators to Identify the Idnase'responsible! Next, morphin'e-lli(e opioids Induce JNK activation, but not GRK/anrestiri- dependent intemalization, whereas high efficacy opioids llie detefgent S.oIubilIzed, adsorbed to Streptavidin resin, then calmodulin resin: The eluted proteins wiilbe digested thei^ resolved t)y 2D niass sjsectroscopy In the UW Proteomics facility. Differences in Isolates from tissues pretreated W.Ith either 'morplilne,'norBNj, fentanyl or U50,488 iand blocked by JNK.Iiiihibitor will be used to Identify critical JNK- suljstrate candidates. ^ :, . . Specific Alth #3 In addition to the discovery based proteomlcapprdach described In aim 2;we will also use a hypothesis driven approach to .assess the role pf predicted candidates. Two plausible JNK targets -are 1) JNK-^hduced ubiquitination of G-alpha.(proteins, and 2) .RGS9.. the former will be assessed.'by I'mmunopreclptitatlon of Gd and Gao and western blotting 43y anti-ubiquit[n antibodies. darz6n has shown that activation.of the .MOR by morphine, results In Grprbteln-uncoupllngelnd sequestration by RGS proteins (Oarz6n 2664 and 2005, Rodrlguez-Munoz 2007y.,Furthenifi'Ore,.RG$ - proteins that are.khdwn to co-localize dnd co-pracipltate with the MOR, such as RGS9 (Zacharlou """"""""2003,..Qarz6n 2005), posses'the archetypical JNK phosphorylation'dpriialh..In'their amino acid . secjUences.. This suggests RGS proteins 0s a potential mechanism fpr morphine-induced receptor desensitization and tolerance, but comparison studies with other MOF^-^elective agonists .^re.lacking. To address the role of JNK In the morphine-induced RGS effects, animals will be-pretreated with. SP600;) 25;(J>iK-l), and we will nfieasure (aa sequestration and RGS actJvafidri following adinihistration - 'of morphine or fentaiiyl using colmmunopreplpitatlon and western blot techniques. Phosphorylatioh-of RGSd will'be measured by precipitating R6S9-2 using antibodies specific'for .the N-tenninu$ (Santa Cruz Biotechnologies) and probing with an antibody generated ag'dlnst .generalphosphorylated serine/threonine reisldues (BD Biosolences). Secjues^atlpn pf Ga subunitsi will be measured by coimmunoprecipitation of F^GSd using IgG antibodies against Ga as a probe;as described (Garz6n. 200S)..lf JNK activation Is required for tiiese evl^nfs. It Is expected thatpretreatmeht with SP600125.will prevent ,RGS phosphorylation and Ga coimrhuiiopreclpltation in tissue from animals treated with'. ? morphine but noil fentanyl. Streptavldlh figure 1: Scheme showing a proposed Calmodulin binding domains cphfiguratloh of the tandem affinity mu opioid receptor complex. We propoise that a JNK substrate Is a vital component of thereceptor signaling complex that becomes inactivated following phosphorylation. -. Dflce 'phosphdiylatadrthe JN|^ substrate^occludesth ,Ga binding idornain of the refeeptor ahcl iiidciis signaling. For kc>i^) this .assqclatlbh. Is'Stable JNK;and pSBuap-lrreyersIble;'for Mdt^ this scibstrate'"""""""" assoclatibn p^'rsi^t^forjess thah'6^^^ for that difference Will become;blearer once.the structures of tlie JNK substrates are determined. JNK. ?fSceS-' Angers S, LI T, YI X, MacCdss MJ, Moon RT, Zheng N. (2006) Molecular architecture ahd assembly of 'tKe. DpB1-c:UL4AUbiqulOniigas6 machinery. W^^^ BQrCkstUmhier^T.KBenriett KL, Pheradovic A, SchOto G, Hantschel 0, Superti-Furga 6, Bauch A. '(2006) Ah efficlerittandern affinity purif^^ procedure for Interaction proteomics In mammalian ,cells.;Klat;Mel;h6dSv3('i2):1p13-S/^ Daulati^-AM;Mauri(iyen""""""""|;P P., Guiilaume, JL., Broussard, C, Monsan^t, Bj, Delagcahg'e, P., Jockerai'Ft. (2067) Puri^ and Identification of GProtelncoupled Receptor Protein Cortiplexes undetNatlve.'GQnditI GarzPh j;Rpdrigf^ez-Mufloz^^ iyiorphine alters the selective association : betweeh-mu-6pIoid receptors and specific RGS proteins In mOuse perlaquediictal gray matter. NeuropheirTn 48: fi53 Gar76n J, Fiodrtgijez-Mufloz M, L6pez-Fando A, Sinchez-Blizquez P. 2005. Activation of |i-oplold Receptdrs trahsferis Control of Ga Subunits to the Regulator of G-prOtelh Signaling RGS9-2. JBC 286(iO):B95l LyssandJS;DeFino MC, Tang XBi Hertz.AL;Feller DB, Wacker JL, Adams ME, Hague C. (2008) BIbbd pressure is regulated by an alphal D-adrenergic receptor/dystrophih signalosome. J Biol C/jem. 283i[27).'18792-i800. ^ Puig 0i,Caspary P,'iRlgaUt:.G, Rutz B, Bouveret E, Bragado-Nilsson E, Wilm M, Si^raphln B^ (2001) The tandem affinity purification (TAP) method: a general procedure of protein complex purification. Methods. 224(3):218-29. Rodrlguei-Muftoz M, BermUdez D, S^nchez-Bldzquez P, Garz6n J. 2007. Suriioylated RGSTRZ Proteins Act as Scaffolds for Mu-Oploid Receptors and G-Protein Complexes In Mouse Brain. Neuropsychopharm 32:842 Zacharlou V, (Seorgescu D, Sanchez N, Rahman Z, DILeone R, Berton O, Neve RL, Sim-Selley LJ, Seiley DE, Gold SJ, Nestler EJ. 2003. Essential role for RGS9 in opiate action. PAMS 100(23): 13656

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
4R37DA011672-11
Application #
7759394
Study Section
Special Emphasis Panel (NSS)
Program Officer
Wu, Da-Yu
Project Start
1999-05-01
Project End
2014-03-31
Budget Start
2009-04-17
Budget End
2010-03-31
Support Year
11
Fiscal Year
2009
Total Cost
$261,747
Indirect Cost
Name
University of Washington
Department
Pharmacology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Kuhar, Jamie Rose; Bedini, Andrea; Melief, Erica J et al. (2015) Mu opioid receptor stimulation activates c-Jun N-terminal kinase 2 by distinct arrestin-dependent and independent mechanisms. Cell Signal 27:1799-806
Chavkin, Charles; Schattauer, Selena S; Levin, Jamie R (2014) Arrestin-mediated activation of p38 MAPK: molecular mechanisms and behavioral consequences. Handb Exp Pharmacol 219:281-92
Chavkin, Charles (2013) Dynorphin--still an extraordinarily potent opioid peptide. Mol Pharmacol 83:729-36
Lemos, Julia C; Roth, Clarisse A; Chavkin, Charles (2011) Signaling events initiated by kappa opioid receptor activation: quantification and immunocolocalization using phospho-selective KOR, p38 MAPK, and K(IR) 3.1 antibodies. Methods Mol Biol 717:197-219
Melief, Erica J; Miyatake, Mayumi; Carroll, F Ivy et al. (2011) Duration of action of a broad range of selective ?-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol 80:920-9
Chavkin, Charles (2011) The therapeutic potential of ?-opioids for treatment of pain and addiction. Neuropsychopharmacology 36:369-70
Aita, Megumi; Byers, Margaret R; Chavkin, Charles et al. (2010) Trigeminal injury causes kappa opioid-dependent allodynic, glial and immune cell responses in mice. Mol Pain 6:8
Melief, Erica J; Miyatake, Mayumi; Bruchas, Michael R et al. (2010) Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A 107:11608-13
Lyssand, John S; Whiting, Jennifer L; Lee, Kyung-Soon et al. (2010) Alpha-dystrobrevin-1 recruits alpha-catulin to the alpha1D-adrenergic receptor/dystrophin-associated protein complex signalosome. Proc Natl Acad Sci U S A 107:21854-9
Clayton, Cecilea C; Bruchas, Michael R; Lee, Michael L et al. (2010) Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy. Mol Pharmacol 77:339-47

Showing the most recent 10 out of 27 publications